Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6477647rdf:typepubmed:Citationlld:pubmed
pubmed-article:6477647lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:6477647lifeskim:mentionsumls-concept:C0012854lld:lifeskim
pubmed-article:6477647lifeskim:mentionsumls-concept:C0028261lld:lifeskim
pubmed-article:6477647lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:6477647lifeskim:mentionsumls-concept:C0026344lld:lifeskim
pubmed-article:6477647pubmed:issue18lld:pubmed
pubmed-article:6477647pubmed:dateCreated1984-10-5lld:pubmed
pubmed-article:6477647pubmed:abstractTextComputer graphics and non-bonded energy calculations have been used to model the intercalative binding of the anti-tumour antibiotic nogalamycin, to double-stranded DNA. The drug is predicted to bind preferentially to A-T rich sites. Specific hydrogen bonds to the exocyclic amino group of adenine bases on the 3' side of an intercalative site have been found by the modelling procedure.lld:pubmed
pubmed-article:6477647pubmed:languageenglld:pubmed
pubmed-article:6477647pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6477647pubmed:citationSubsetIMlld:pubmed
pubmed-article:6477647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6477647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6477647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6477647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6477647pubmed:statusMEDLINElld:pubmed
pubmed-article:6477647pubmed:monthSeplld:pubmed
pubmed-article:6477647pubmed:issn0006-2952lld:pubmed
pubmed-article:6477647pubmed:authorpubmed-author:BrownJ RJRlld:pubmed
pubmed-article:6477647pubmed:authorpubmed-author:NeidleSSlld:pubmed
pubmed-article:6477647pubmed:authorpubmed-author:CollierD ADAlld:pubmed
pubmed-article:6477647pubmed:issnTypePrintlld:pubmed
pubmed-article:6477647pubmed:day15lld:pubmed
pubmed-article:6477647pubmed:volume33lld:pubmed
pubmed-article:6477647pubmed:ownerNLMlld:pubmed
pubmed-article:6477647pubmed:authorsCompleteYlld:pubmed
pubmed-article:6477647pubmed:pagination2877-80lld:pubmed
pubmed-article:6477647pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:meshHeadingpubmed-meshheading:6477647-...lld:pubmed
pubmed-article:6477647pubmed:year1984lld:pubmed
pubmed-article:6477647pubmed:articleTitleMolecular models for the interaction of the anti-tumour drug nogalamycin with DNA.lld:pubmed
pubmed-article:6477647pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6477647pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6477647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6477647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6477647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6477647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6477647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6477647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6477647lld:pubmed